Melbourne, Aug 12, 2008 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced successful preclinical trial results which showed that its proprietary adult stem cells regenerated and regrew damaged knee cartilage in post-menopausal osteoarthritis.
